| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Lipid bilayers and membrane phospholipids. Specifically, BODIPY FL-DHPE integrates into the lipid bilayer by inserting its DHPE tail into the hydrophobic core, while the BODIPY fluorophore resides near the polar headgroup region. This probe targets 1,2-dihexadecanoyl-sn-glycero-phosphoethanolamine (DHPE), a synthetic phospholipid commonly used in model membrane systems. It enables the visualization of membrane architecture, lipid organization, and dynamic processes such as membrane fusion, lipid raft formation, and vesicle trafficking in living cells.
|
|---|---|
| ln Vitro |
In vitro, BODIPY FL-DHPE is used to label synthetic liposomes composed of DHPE or mixtures of phospholipids. The labeled liposomes retain their structural integrity and fusogenic properties. Studies demonstrate that BODIPY FL-DHPE-labeled liposomes can be internalized by various cell lines through membrane fusion pathways, allowing real-time tracking of lipid mixing and cargo delivery. The dye exhibits high photostability, low cytotoxicity, and minimal spectral overlap with other common fluorophores, facilitating multi-color imaging experiments. It is also used to assess membrane fluidity, lipid packing, and protein-lipid interactions in supported lipid bilayers and live cell membranes.
|
| ln Vivo |
In vivo, BODIPY FL-DHPE-labeled liposomes have been employed to study the biodistribution of phospholipid-based carriers. After systemic administration, labeled liposomes accumulate in tissues such as the liver, spleen, and lungs, depending on their size, surface charge, and lipid composition. The fluorescence signal allows tracking of liposome localization and clearance over time. BODIPY FL-DHPE has also been used in live animal imaging to investigate membrane fusion events at the whole-organism level, particularly in models of endocytosis, phagocytosis, and viral entry. The dye's green emission enables multiplexing with red or far-red probes for combined imaging of multiple processes.
|
| Enzyme Assay |
For a non-cellular binding assay, BODIPY FL-DHPE is first incorporated into liposomes at a concentration of 0.1-1 mol% relative to total lipid. Liposomes are prepared by dissolving the lipid mixture (e.g., DOPC, DOPE, and cholesterol) in chloroform, followed by solvent evaporation under nitrogen to form a thin film. The film is hydrated with buffer (e.g., PBS, pH 7.4) and extruded through polycarbonate membranes (100 nm pore size) to generate unilamellar vesicles. Fluorescence intensity is measured using a fluorimeter or plate reader at λex/λem of 485/535 nm to confirm incorporation. For membrane fusion assays, labeled liposomes are mixed with unlabeled target liposomes, and fluorescence dequenching (due to dilution of the probe) is monitored over time following the addition of fusogenic agents (e.g., Ca2+, PEG).
|
| Cell Assay |
Cells (e.g., HeLa, CHO, or primary neurons) are seeded in chambered cover slips or 96-well plates at 1×10⁴-5×10⁴ cells/well 24 hours prior to staining. BODIPY FL-DHPE is prepared as a 1 mM stock solution in DMSO, then diluted to a working concentration of 1-10 microM in serum-free medium or PBS. Cells are incubated with the dye for 15-30 minutes at 37degC to allow membrane incorporation. After staining, the medium is replaced with fresh medium to remove unbound dye. Fluorescence imaging is performed using a confocal laser scanning microscope with excitation at 488 nm (Argon laser) and emission collection at 505-550 nm. For flow cytometry analysis, stained cells are detached with trypsin, washed with PBS, resuspended at 1×10⁶ cells/mL, and analyzed on a flow cytometer equipped with a 488 nm laser and FITC channel.
|
| Animal Protocol |
A typical in vivo imaging protocol involves preparing BODIPY FL-DHPE-labeled liposomes at a concentration of 1-10 mg total lipid/mL in sterile PBS. For intravenous administration, 100-200 uL of liposome suspension is injected into the tail vein of mice (C57BL/6, 6-8 weeks old). At predetermined time points (e.g., 1, 4, 8, 24, 48 hours post-injection), mice are anesthetized with isoflurane and imaged using an in vivo fluorescence imaging system (e.g., IVIS Spectrum) with excitation at 480-500 nm and emission at 510-540 nm. For ex vivo analysis, mice are euthanized, and organs (liver, spleen, kidney, lung, heart) are harvested for fluorescence imaging and quantification. Tissue sections are also prepared for histological analysis to confirm membrane localization of the probe.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies of BODIPY FL-DHPE-labeled liposomes indicate a biphasic clearance pattern from the bloodstream, with an initial distribution half-life (t1/2alpha) of approximately 5-15 minutes and a terminal elimination half-life (t1/2beta) of 2-4 hours. The probe accumulates primarily in the liver (30-50% of injected dose) and spleen (10-20%) within 30 minutes post-injection, owing to uptake by the mononuclear phagocyte system. Renal clearance is minimal due to the high molecular weight of the liposomal formulation. The fluorescence signal in blood declines rapidly within 4 hours, while tissue-associated fluorescence persists for up to 48 hours. The area under the curve (AUC) is dose-dependent, and the volume of distribution reflects confinement to the vascular and reticuloendothelial compartments.
|
| Toxicity/Toxicokinetics |
Acute toxicity studies of BODIPY FL-DHPE demonstrate low cytotoxicity in vitro across a concentration range of 0.1-100 uM, with no significant reduction in cell viability compared to untreated controls. In vivo, no acute adverse effects or mortality are observed at doses up to 10 mg/kg in mice. Sub-chronic administration (3-5 daily doses) shows no significant changes in body weight, organ weight, serum biochemistry (ALT, AST, creatinine), or complete blood count. Histopathological evaluation of major organs reveals no drug-related abnormalities. The probe exhibits high biocompatibility due to its phospholipid-like structure. However, users should handle it with standard laboratory precautions and avoid repeated freeze-thaw cycles, which may affect fluorescence intensity.
|
| References | |
| Additional Infomation |
BODIPY FL-DHPE is a research-grade fluorescent probe not approved for clinical use. It is particularly useful for studying both membrane surfaces and membrane fusion processes. The probe is supplied as a lyophilized powder and should be stored at -20degC, protected from light, to maintain stability. Reconstituted stock solutions in DMSO or ethanol can be stored at -20degC for up to 3 months. When handling, avoid exposing the dye to strong acids or bases, as the BODIPY core may be unstable under extreme pH conditions. The probe is compatible with formaldehyde fixation, allowing staining of both live and fixed cells. For optimal results, the working concentration should be empirically determined for each cell type and experimental condition.
|
| Molecular Formula |
C51H86BN3O9F2P-.C6H15N.H+
|
|---|---|
| Molecular Weight |
1067.22
|
| Exact Mass |
1066.745
|
| CAS # |
217075-07-5
|
| PubChem CID |
172653035
|
| Appearance |
Orange to red solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
46
|
| Heavy Atom Count |
74
|
| Complexity |
1600
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[H+].C(C1=CC=C2C=C3C(C)=CC(C)=N3[B+3]([F-])([F-])[N-]12)CC(=O)NCCOP([O-])(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC.N(CC)(CC)CC
|
| InChi Key |
QCZJEDYSQWSMRR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C51H87BF2N3O9P.C6H15N/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-50(59)63-41-47(66-51(60)32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)42-65-67(61,62)64-38-37-55-49(58)36-35-45-33-34-46-40-48-43(3)39-44(4)56(48)52(53,54)57(45)46;1-4-7(5-2)6-3/h33-34,39-40,47H,5-32,35-38,41-42H2,1-4H3,(H,55,58)(H,61,62);4-6H2,1-3H3
|
| Chemical Name |
N,N-diethylethanamine;2-[3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)propanoylamino]ethyl 2,3-di(hexadecanoyloxy)propyl phosphate;hydron
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9370 mL | 4.6851 mL | 9.3701 mL | |
| 5 mM | 0.1874 mL | 0.9370 mL | 1.8740 mL | |
| 10 mM | 0.0937 mL | 0.4685 mL | 0.9370 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
